Molecular Tumor Board Solutions Market Report 2026

Molecular Tumor Board Solutions Market Overview

• Molecular Tumor Board Solutions market size has reached to $1.53 billion in 2025 • Expected to grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 13.4% • Growth Driver: Rising Prevalence Of Cancer Fueling The Growth Of The Market Due To Increasing Patient Demand For Personalized And Precise Treatment Strategies • Market Trend: Innovative Molecular Profiling Enhances Cancer Treatment Precision • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Molecular Tumor Board Solutions Market?

Molecular tumor board solutions are advanced platforms designed to assist multidisciplinary clinical teams in comprehensively analyzing cancer cases by integrating detailed patient-specific molecular and genomic information. These solutions facilitate the identification of actionable genetic mutations, the evaluation of targeted therapy options, and the discussion of suitable clinical trials, thereby supporting informed and personalized treatment decisions for patients. The main types of components in molecular tumor board solutions are software and services. Software refers to digital platforms and applications designed to integrate patient data, analyze genetic profiles, and provide treatment recommendations for cancer care. These can be deployed via on-premises or cloud-based solutions and cater to applications such as clinical decision support, genomic data interpretation, patient management, and others, serving end users such as hospitals, cancer centers, research institutes, and others.

What Is The Molecular Tumor Board Solutions Market Growth Forecast?

The molecular tumor board solutions market size is expected to see rapid growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing investments in personalized cancer treatment, rising demand for molecularly guided therapies, expansion of cloud deployment in healthcare, growing integration with clinical trial matching platforms, increasing adoption of ai-driven oncology analytics. Major trends in the forecast period include increasing use of AI-assisted variant interpretation, growing integration of multimodal genomic data, expansion of cloud-based tumor board platforms, rising adoption of collaborative decision support tools, enhanced focus on personalized oncology workflows.

What Is The Driver Of The Molecular Tumor Board Solutions Market?

The rising prevalence of cancer is expected to propel the growth of the molecular tumor board solutions market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Molecular tumor board solutions aid in cancer care by providing expert, multidisciplinary review of patients’ genomic and clinical data, enabling personalized treatment strategies. They enhance clinical decision-making by integrating molecular profiling and AI-driven insights, improving patient outcomes and treatment precision. For instance, in February 2024, according to the World Health Organization, a Switzerland-based global public health agency, reported that over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the molecular tumor board solutions industry.

Key Players In The Global Molecular Tumor Board Solutions Market

Major companies operating in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, CureMatch Inc.

Global Molecular Tumor Board Solutions Market Trends and Insights

Major companies operating in the molecular tumor board solutions market are focusing on developing innovative solutions, such as molecular profiling tests, to enhance the accuracy and effectiveness of cancer diagnostics and treatment planning. Molecular profiling tests are diagnostic tests that analyze a tumor’s genetic and molecular characteristics to guide personalized cancer treatment decisions. For instance, in April 2025, Guardant Health Inc., a US-based biotechnology and precision oncology company, launched Guardant360 Tissue, a groundbreaking molecular profiling test for tumor tissue that integrates comprehensive multiomic analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. This advanced test, powered by the Guardant Infinity smart liquid biopsy platform, offers a more complete and multidimensional view of cancer, enabling higher resolution tumor classification and subtyping. Guardant360 Tissue delivers results in under two weeks, is covered by Medicare for eligible patients, and aims to enhance precision oncology by providing deeper insights to guide treatment decisions, including for therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies.

What Are Latest Mergers And Acquisitions In The Molecular Tumor Board Solutions Market?

In September 2024, Labcorp Holdings Inc., a US-based healthcare company, acquired BioReference Health LLC for $237.5 million. With this acquisition, Labcorp aims to expand its laboratory services network and increase access to its clinical testing capabilities for patients, physicians, and customers in key regions. BioReference Health LLC is a US-based company that offers molecular tumor board solutions by providing comprehensive genomic testing and a portfolio of tests.

What Defines the Molecular Tumor Board Solutions Market?

The molecular tumor board solutions market includes revenues earned by entities through providing expert clinical consultations, personalized treatment recommendations, and decision-support services to healthcare providers and patients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Molecular Tumor Board Solutions Market Report 2026?

The molecular tumor board solutions market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the molecular tumor board solutions industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.